The trial was suspended after interim analysis had shown that the vaccine did not protect the trial participants against HIV infection, and even more important, participants who had received the vaccine and became HIV infected did not have a lower viral load set-point despite having robust CD8+ T-cell responses to the vaccine components (Gag, Nef and Pol) after vaccination. The gene discussed is S100B; the disease is HIV infectious disease.